Proceeds support the continued clinical development of TRB-061, a novel TNFR2 agonist designed to selectively activate regulatory T cells (“Tregs”) in inflammatory diseases affecting skin and other barrier tissues, including atopic dermatitis The single ascending dose portion of the ongoing Phase 1a/b clinical trial of TRB-061 has been completed, with the multiple ascending dose portion underway Financing also enables TRB-071 and TRB-081, two mechanistically distinct preclinical programs from

Jan. 27, 2026 -- Antheia, the advanced biosynthesis company delivering 21st-century pharmaceutical manufacturing and innovation, today announced it has completed a second close of its Series C financing, raising an additional $24 million. Combined with additional available capital and non-dilutive funding, including multiple project agreements with the U.S. government, the company has secured more than $175 million over the past year. Proceeds from the financing will be used to expand Antheia's

Jan. 26, 2026 -- Today, Primmune Therapeutics, a biotech company harnessing the power of the innate immune system, announced an additional close of its Series B financing round for a total of $8.6 million with participation from Bioqube Ventures, Oberland Capital and Samsara Biocapital. This close brings the total Series B raise to $23.3 million. These funds will be used to support the further clinical development of PRTX007, a novel orally administered, systemically acting, small molecule toll

Jan. 22, 2026 -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, announced today it has completed a $90 million strategic investment from Medtronic, plc (Galway, Ireland) (NASDAQ: MDT) (Medtronic), the world’s largest medical technology company. The investment closed immediately following Anteris’ underwritten

Corxel will use the fundraising proceeds to advance the oral GLP-1 therapy CX11 through mid-stage development in the U.S., as well as prepare for its Phase III studies. Corxel Pharmaceuticals has brought in $287 million from its series D1 fundraising push, giving it enough money to advance its oral GLP-1 drug CX11, among other pipeline candidates. In particular, Corxel, which has offices in New Jersey, Hong Kong, Shanghai and Beijing, will use the proceeds to complete Phase II testing for CX11

Think Bioscience has raised a $55 million Series A led by investors including Regeneron Ventures, Innovation Endeavors and Janus Henderson. The University of Colorado spinout is crafting small molecules aimed at difficult-to-drug targets. While many so-called “undruggable” startups have focused on cancer, Think Bio is developing a treatment for a genetic disease called Noonan syndrome, which it says impacts around one in 2,500 births and can lead to a wide set of symptoms, including heart probl

Jan. 22, 2026 -- PAQ Therapeutics, a clinical-stage oncology company developing novel targeted protein degradation therapies for KRAS-driven cancers, today announced the closing of a Series B extension, bringing the company's total Series B financing to $77 million, and the dosing of the first patient in a Phase 1 clinical trial evaluating PT0511, the company's pan-KRAS degrader. The Series B extension builds on PAQ's previously announced Series B financing, with participation from existing as

Mendra, Inc. (“Mendra”), a biopharmaceutical company built to advance promising therapies for rare disease medicines, utilizing artificial intelligence (AI), today announced its launch in conjunction with the closing of an $82 million oversubscribed Series A financing. The round was co-led by OrbiMed, 8VC, and 5AM Ventures with participation from Lux Capital and Wing VC. Mendra aims to modernize the development and commercialization of rare disease therapies to more efficiently reach patients o

Infinitopes said Wednesday it closed the second tranche of its seed financing round, raising an additional $15.4 million to bring total proceeds to $35.1 million, as the UK-based biotech prepares to launch a first-in-human study of its lead asset ITOP1 — an 'off-the-shelf' precision cancer vaccine targeting oesophageal cancer recurrence. The latest investment was co-led by Octopus Ventures and new backer Amplify Bio, with participation from new investor Macmillan Cancer Support and existing sup

Jan. 20, 2026 -- Think Bioscience ("Think Bio"), a biotechnology company focused on unlocking elusive drug targets, has raised $55M in an oversubscribed Series A. The round was led by Regeneron Ventures, Innovation Endeavors, and Janus Henderson Investors with participation from T.A. Springer, CE-Ventures, MBX Capital, and YK Bioventures. Returning investors include AV8 Ventures, CU Innovations, and Buff Gold Ventures. Think Bioscience develops small molecule drugs for historically challenging